Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

F. Palandri,G. Auteri,E. Abruzzese,G. Caocci, M. Bonifacio,F. Mendicino,R. Latagliata, A. Iurlo, F. Branzanti,B. Garibaldi,M. M. Trawinska, D. Cattaneo, M. Krampera,O. Mulas,E. A. Martino,M. Cavo, N. Vianelli,S. Impera,F. Efficace,F. Heidel,M. Breccia,E. M. Elli,G. A. Palumbo

Annals of Hematology（2024）

Cited 0|Views5

No score

Abstract

Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. The Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP) prospective multicenter study (NCT06078319) included 189 ruxolitinib-treated patients. Patients completed the Adherence to Refills and Medications Scale (ARMS) and Distress Thermometer and Problem List (DTPL) at the earliest convenience, after registration in the study, and at later timepoints. At week-0, low adherence (ARMS > 14) and high distress (DT ≥ 4) were declared by 49.7

Translated text

Key words

Adherence to medication,Ruxolitinib,Myelofibrosis,Polycythemia Vera,Distress,Adherence

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined